Accelerate past the financial hurdles of discovery
When we see the potential in your business, we consider sharing in the financial risk to make that potential a reality.
FemtaFemta Pharmaceuticals is fast-follower/bio-better company focused on the development of therapeutic monoclonal antibodies for the treatment of various disease states in the areas of inflammation, autoimmune disease and oncology.,
VivaMab,VivaMab LLC is a biopharmaceutical company developing a portfolio of bio-better protein therapeutics products for a broad range of therapeutic areas.
Inhibrx.InhibRx is taking an innovative approach to developing a portfolio of proprietary therapeutic antibody products against highly validated disease targets with large unmet medical needs by leveraging a small but highly experienced management and scientific team across a large portfolio of antibody projects and utilizing a strategic partner network of top quality service providers.
Our focus on delivering cost-effective services extends to more traditional project-by-project relationships, too. Find the solution that fits your budget with our gold and silver pricing packages. And pay for only what you need, as we pinpoint and deliver on a highly specific requirement within your discovery process. Financial partnerships are rapidly replacing the traditional drug discovery business models that are simply no longer sustainable – and BioAtla is leading the way. So whether you are looking for a simple services-for-fee arrangement or a custom multi-year program, we have the experience and compensation option for you. That’s the BioAcceleration™ difference.
Put our flexible collaborative strategy to work for you. Learn more by calling 858-558-0708 ext. 0 or send us an email.